Connor Clark & Lunn Investment Management Ltd. Has $28.10 Million Position in Eli Lilly and Company (NYSE:LLY)

Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 16.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,018 shares of the company’s stock after buying an additional 4,688 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Eli Lilly and Company were worth $28,096,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Cynosure Group LLC boosted its stake in shares of Eli Lilly and Company by 6.9% during the 1st quarter. Cynosure Group LLC now owns 1,667 shares of the company’s stock valued at $1,377,000 after buying an additional 107 shares during the period. Riverpark Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 14.2% during the 1st quarter. Riverpark Capital Management LLC now owns 3,087 shares of the company’s stock valued at $2,550,000 after purchasing an additional 383 shares in the last quarter. Donoghue Forlines LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at $2,261,000. Zions Bancorporation National Association UT bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at $11,033,000. Finally, Townsquare Capital LLC raised its holdings in shares of Eli Lilly and Company by 32.2% during the 1st quarter. Townsquare Capital LLC now owns 74,353 shares of the company’s stock valued at $61,410,000 after purchasing an additional 18,118 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $625.15 on Friday. The company has a market capitalization of $592.48 billion, a PE ratio of 40.86, a price-to-earnings-growth ratio of 0.89 and a beta of 0.44. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The company’s fifty day moving average price is $774.10 and its 200 day moving average price is $799.11.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 98.25%. The business’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the business posted $3.92 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 1.0%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on LLY shares. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday. Morgan Stanley restated an “overweight” rating and set a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $984.41.

Insider Transactions at Eli Lilly and Company

In related news, Director Jamere Jackson purchased 200 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director directly owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.